182 related articles for article (PubMed ID: 27861357)
1. The effect of alprostadil on preventing contrast-induced nephropathy for percutaneous coronary intervention in diabetic patients: A systematic review and meta-analysis.
Ye Z; Lu H; Guo W; Dai W; Li H; Yang H; Li L
Medicine (Baltimore); 2016 Nov; 95(46):e5306. PubMed ID: 27861357
[TBL] [Abstract][Full Text] [Related]
2. Effect of Alprostadil on the Prevention of Contrast-Induced Nephropathy: A Meta-Analysis of 36 Randomized Controlled Trials.
Xie J; Jiang M; Lin Y; Deng H; Li L
Angiology; 2019 Aug; 70(7):594-612. PubMed ID: 30669852
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of alprostadil for preventing of contrast-induced nephropathy: A meta-analysis.
Zhang JZ; Kang XJ; Gao Y; Zheng YY; Wu TT; Li L; Liu F; Yang YN; Li XM; Ma YT; Xie X
Sci Rep; 2017 Apr; 7(1):1045. PubMed ID: 28432310
[TBL] [Abstract][Full Text] [Related]
4. Prevention of contrast-induced nephropathy with prostaglandin E1 in patients undergoing percutaneous coronary procedures: A meta-analysis of 24 randomized controlled trials
.
Liu X; Hang Y; Shen L; Yang J; Zhou L; Sha W; Lu G
Clin Nephrol; 2018 Nov; 90(5):313-324. PubMed ID: 30106366
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Prevention of contrast-induced nephropathy with prostaglandin E1 in high-risk patients undergoing percutaneous coronary intervention.
Li WH; Li DY; Qian WH; Liu JL; Xu TD; Zhu H; He HY
Int Urol Nephrol; 2014 Apr; 46(4):781-6. PubMed ID: 24570327
[TBL] [Abstract][Full Text] [Related]
7. Clinical effect of trimetazidine on prevention of contrast-induced nephropathy in patients with renal insufficiency: An updated systematic review and meta-analysis.
Ye Z; Lu H; Su Q; Guo W; Dai W; Li H; Yang H; Li L
Medicine (Baltimore); 2017 Mar; 96(9):e6059. PubMed ID: 28248861
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Alprostadil in Preventing Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis.
Xu H; Wang H; Zhang C; Xiao J; Hua N; Tang X; Xie J; Zhang Z
Angiology; 2021 Oct; 72(9):878-888. PubMed ID: 33853365
[TBL] [Abstract][Full Text] [Related]
9. Xuebijing injection combined with alprostadil in the treatment of diabetic nephropathy: A PRISMA-compliant systematic review and meta-analysis.
Hao N; Liu Y; Guo L; Li W; Zhao P
Medicine (Baltimore); 2024 Jun; 103(24):e32095. PubMed ID: 38875385
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A multicenter prospective randomized controlled trial.
Liang M; Yang S; Fu N; Lu C; Tian F; Xing X; Lin W; Liu J
Catheter Cardiovasc Interv; 2018 Mar; 91(4):742-750. PubMed ID: 29024304
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis on allopurinol preventive intervention on contrast-induced acute kidney injury with random controlled trials: PRISMA.
Ma G; Wang G; Xiao D; Teng W; Hui X; Ma G
Medicine (Baltimore); 2019 Jun; 98(25):e15962. PubMed ID: 31232927
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Predictors of Contrast-Induced Nephropathy (CIN) in Patients with ST-Segment Elevation Myocardial Infarction (STEMI) Undergoing Percutaneous Coronary Intervention (PCI): A Meta-Analysis.
He H; Chen XR; Chen YQ; Niu TS; Liao YM
J Interv Cardiol; 2019; 2019():2750173. PubMed ID: 31772520
[TBL] [Abstract][Full Text] [Related]
13. Preventing contrast-induced acute kidney injury with probucol and hydration in patients with coronary heart disease: A systematic review and meta-analysis of randomized controlled trials.
Cui X; Xie B; Wang H; Liu F; Mei L; Qin F; Zhang J; Yi X
Medicine (Baltimore); 2023 Mar; 102(11):e33273. PubMed ID: 36930109
[TBL] [Abstract][Full Text] [Related]
14. Alprostadil plays a protective role in contrast-induced nephropathy in the elderly.
Miao Y; Zhong Y; Yan H; Li W; Wang BY; Jin J
Int Urol Nephrol; 2013 Aug; 45(4):1179-85. PubMed ID: 23860961
[TBL] [Abstract][Full Text] [Related]
15. Effect of Nicorandil Administration on Preventing Contrast-Induced Nephropathy: A Meta-Analysis.
Zhan B; Huang X; Jiang L; Bao H; Cheng X
Angiology; 2018 Aug; 69(7):568-573. PubMed ID: 28950711
[TBL] [Abstract][Full Text] [Related]
16. Preventive Effects of Alprostadil Against Contrast-Induced Nephropathy Inpatients With Renal Insufficiency Undergoing Percutaneous Coronary Intervention.
Yang SC; Fu NK; Zhang J; Liang M; Cong HL; Lin WH; Tian FS; Lu CZ; Sun TT; Zhang WY; Ma ZH
Angiology; 2018 May; 69(5):393-399. PubMed ID: 29073785
[TBL] [Abstract][Full Text] [Related]
17. [Meta-analysis on efficacy of salvianolate in prevention of contrast-induced nephropathy].
Xi YT; Yuan LY; Xu ST; Liu XY; Wu W
Zhongguo Zhong Yao Za Zhi; 2019 Jun; 44(12):2616-2626. PubMed ID: 31359732
[TBL] [Abstract][Full Text] [Related]
18. Alprostadil protects type 2 diabetes mellitus patients treated with metformin from contrast-induced nephropathy.
Wang J; Ai X; Li L; Gao Y; Sun N; Li C; Sun W
Int Urol Nephrol; 2017 Nov; 49(11):2019-2026. PubMed ID: 28656510
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: A meta-analysis of 15 randomized controlled trials.
Liang M; Yang S; Fu N
Medicine (Baltimore); 2017 Jul; 96(27):e7384. PubMed ID: 28682890
[TBL] [Abstract][Full Text] [Related]
20. The Preventive Effect of Alprostadil on the Contrast-Induced Nephropathy of Coronary Heart Disease Treated by Percutaneous Coronary Intervention in Moderate and High-Risk Population Stratified by Mehran Score.
Liu X; Zhang P; Zhang J; Zhang X; Yang S; Fu N
Angiology; 2022 Jan; 73(1):33-41. PubMed ID: 34098771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
